The Pharmaceutical Journal
Vol 273 No 7329 p850
11 December 2004

This article
Reprint   Photocopy

PDF 100K, Acrobat Reader

· New contract (5)
· PPRS
· Registration exam (4)
· Prescription forms
· Community pharmacy
· Male health
· Competency
· Public health
· Alcohol
· Levithyroxine
· Complementary medicine
· The register (3)
· Retention fee
· The Journal (2)

Letters to the Editor

PPRS

Ups and downs

From Mr D. J. Hamblin, MRPharmS

The daunting prospect of having to deal with the pending 7 per cent Pharmaceutical Price Regulation Scheme reduction in branded prescription drugs (PJ, 6 November, p669) at one of the busiest times of the year has been somewhat improved by the much welcomed letters from AstraZeneca and GlaxoSmithKline informing of their intentions in good time. Let us hope that the rest of the industry can be similarly transparent.

AstraZeneca has announced significant cuts on four major products. Does this give scope for an increase on the rest of their portfolio?

David Hamblin
Norwich, Norfolk

Send your letter to The Editor

Previous Topic (New contract)
Next Topic (Registration exam)